| Titel |
Royal Jelly Protects Heart from Chemotherapy Damage |
| Subtitel |
Cardioprotective effect of royal jelly on paclitaxel-induced cardio-toxicity in rats |
| Author |
Malekinejad, Ahsan, Delkhosh-Kasmaie, Cheraghi, Rezaei-Golmisheh, Janbaz-Acyabar. |
|
|
| Abstract |
OBJECTIVES:
Paclitaxel is a potent chemotherapy agent with severe side effects, including allergic reactions, cardiovascular problems, complete hair loss, joint and muscle pain, which may limit its use and lower its efficiency. The cardioprotective effect of royal jelly was investigated on paclitaxel-induced damages. |
| Methods |
MATERIALS AND METHODS:
Adult male Wistar rats were divided into control and test groups (n=8). The test group was assigned into five subgroups; 4 groups, along with paclitaxel administration (7.5 mg/kg BW, weekly), received various doses of royal jelly (50, 100, and 150 mg/kg BW) for 28 consecutive days. The last group received only royal jelly at 100 mg/kg. In addition to oxidative and nitrosative stress biomarkers, the creatine kinase (CK-BM) level was also determined. To show the cardioprotective effect of royal jelly on paclitaxel-induced damages, histopathological examinations were conducted. |
| Results |
RESULTS:
Royal jelly lowered the paclitaxel-elevated malondialdehyde and nitric oxide levels in the heart. Royal jelly could also remarkably reduce the paclitaxel-induced cardiac biomarker of creatine kinase (CK-BM) level and pathological injuries such as diffused edema, hemorrhage, congestion, hyaline exudates, and necrosis. Moreover, royal jelly administration in a dose-dependent manner resulted in a significant (P<0.05) increase in the paclitaxel-reduced total antioxidant capacity. |
| Conclusions |
|
|
|
| http://doi.org / URL |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818372/ |
| Published |
Iran J Basic Med Sci. 2016 Feb;19(2):221-7. |
Lehnherr, Mathias (8. Aufl. 2017) [1992]: Imkerbuch
